Table 2 Ongoing Clinical Trials in Anaplastic Thyroid Cancer (as on July 15, 2018), listed from https://clinicaltrials.gov/
From: Therapeutic advances in anaplastic thyroid cancer: a current perspective
S. No | Phase | Drug | Drug Action | Clinical Trial No. | Status | Sponsors |
|---|---|---|---|---|---|---|
1 | II | MLN0128 | mTOR kinase inhibitor | NCT02244463 | Recruiting | Dana-Farber Cancer Institute, USA |
2 | II | Lenvatinib | MKI against VEGFR1, 2, and 3 | NCT02726503 | Recruiting | Translational Research Informatics Center, Kobe, Hyogo, Japan |
NCT02657369 | Recruiting | Eisai Inc. USA | ||||
3 | Early phase I | Trametinib in combination with Paclitaxel | MEK inhibitor (Trametinib) with chemotherapy | NCT03085056 | Recruiting | Memorial Sloan Kettering Cancer Center, USA |
4 | II | Pembrolizumab | Antibody against PD-1 receptor | NCT02688608 | Recruiting | University of Texas Southwestern Medical Center, USA |
5 | II | Inolitazone Dihydrochloride (Efutazone) and Paclitaxel | PPAR-γ agonist (Efutazone) with chemotherapy | NCT02152137 | Recruiting | Alliance for Clinical Trials in Oncology, USA |
6 | I | Combination of Durvalumab (MEDI4736) or Tremelimumab with Stereotactic Body Radiotherapy (SBRT) | Checkpoint inhibitor drugs: Durvalumab (PD-1/PDL-1 interaction blocker) and Tramelimumab (anti-CTLA4 antibody) with radiations | NCT03122496 | Recruiting | Memorial Sloan Kettering Cancer Center, USA |
7 | II | Intensity-Modulated Radiation Therapy and Paclitaxel with or Without Pazopanib Hydrochloride | Pazopanib is a MKI against c-kit, FGFR, PDGFR and VEGFR | NCT01236547 | Ongoing but not yet recruiting participants | National Cancer Institute (NCI), USA |
8. | II | Ceritinib | ALK inhibitor | NCT02289144 | Recruiting | University of Texas Southwestern Medical Center, USA |
9 | II | Atezolizumab Combinations with or without chemotherapy such as paclitaxel, Vemurifinib, Nab-paclitaxel, Cobimetinib and Bevacizumab | anti-PDL-1 antibody (Atezolizumab) | NCT03181100 | Recruiting | M.D. Anderson Cancer Center, USA |
10 | I | FAZ053 as Single Agent and in combination with PDR001 | FAZ053 is anti-PDL-1 antibody and PDR001 is monoclonal antibody against PD-1. | NCT02936102 | Recruiting | Novartis Pharmaceuticals, USA |
11 | II | Dabrafenib and Trametinib | Dabrafenib acts against BRAFV600E mutations and Trametinib is MEK (1 and 2) inhibitor | NCT02034110 | Recruiting | GlaxoSmithKline, USA |
12 | II | GW 786034 (Pazopanib Hydrochloride) | Pazopanib is a MKI against c-kit, FGFR, PDGFR and VEGFR | NCT00625846 | Active, not recruiting | National Cancer Institute (NCI), USA |
13 | II | Pembrolizumab, Chemotherapy,and Radiation Therapy With or Without Surgery | anti-PD1 immunotherapy | NCT03211117 | Active, not recruiting | Mayo Clinic,National Cancer Institute (NCI), USA |
14 | I/II | PDR001 | anti-PD1 monoclonal antibody | NCT02404441 | Recruiting | Novartis Pharmaceuticals |